Payment overview · 2025
General Payments
$42.02
2 reported records · 2 companies
Healthcare provider profile · identity verified
Zena Abd-Alahad
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · TOLEDO, OH · NPI 1659878239
Verified facts
What the public records show
CMS Open Payments records show Zena Abd-Alahad received $42.02 in general payments during 2025 across 2 reported records.
Neurocrine BioSciences, Inc. accounted for 50.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ingrezza by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $21.16 | 50.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.86 | 49.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $42.02 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 653 | 146 |
| Eliquis | Apixaban | 609 | 75 |
| Potassium Chloride | Potassium Chloride | 392 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 350 | 65 |
| Gabapentin | Gabapentin | 342 | 83 |
| Furosemide | Furosemide | 338 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 318 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 302 | 81 |
| Sertraline Hcl | Sertraline Hcl | 285 | 61 |
| Trazodone Hcl | Trazodone Hcl | 231 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 229 | 58 |
| Buspirone Hcl | Buspirone Hcl | 220 | 51 |
| Lisinopril | Lisinopril | 219 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 211 | 46 |
| Omeprazole | Omeprazole | 207 | 48 |
| Donepezil Hcl | Donepezil Hcl | 192 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 188 | 42 |
| Mirtazapine | Mirtazapine | 185 | 38 |
| Xarelto | Rivaroxaban | 180 | 21 |
| Carvedilol | Carvedilol | 177 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 175 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 45 |
| Cephalexin | Cephalexin | 155 | 65 |
| Levetiracetam | Levetiracetam | 154 | 30 |
| Metformin Hcl | Metformin Hcl | 151 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 144 | 28 |
| Memantine Hcl | Memantine Hcl | 128 | 22 |
| Losartan Potassium | Losartan Potassium | 123 | 28 |
| Famotidine | Famotidine | 103 | 31 |
| Jardiance | Empagliflozin | 103 | 20 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 102 | 22 |
| Bumetanide | Bumetanide | 102 | 31 |
| Spironolactone | Spironolactone | 100 | 34 |
| Midodrine Hcl | Midodrine Hcl | 97 | 41 |
| Divalproex Sodium | Divalproex Sodium | 95 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 91 | 17 |
| Baclofen | Baclofen | 84 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 84 | 17 |
| Warfarin Sodium | Warfarin Sodium | 80 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 17 |
| Latanoprost | Latanoprost | 72 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 49 |
| Januvia | Sitagliptin Phosphate | 67 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 65 | 37 |
| Alendronate Sodium | Alendronate Sodium | 64 | 13 |
| Allopurinol | Allopurinol | 64 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 63 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 62 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 16 |
| Prednisone | Prednisone | 60 | 29 |
| Aripiprazole | Aripiprazole | 58 | 12 |
| Torsemide | Torsemide | 58 | suppressed |
| Enulose | Lactulose | 56 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 11 |
| Glimepiride | Glimepiride | 52 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 20 |
| Finasteride | Finasteride | 51 | suppressed |
| Novolog Flexpen | Insulin Aspart | 51 | 14 |
| Atenolol | Atenolol | 50 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 24 |
| Farxiga | Dapagliflozin Propanediol | 46 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 46 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | suppressed |
| Rivastigmine | Rivastigmine | 45 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 24 |
| Olanzapine | Olanzapine | 43 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Lorazepam | Lorazepam | 41 | 16 |
| Albuterol Sulfate | Albuterol Sulfate | 40 | 23 |
| Risperidone | Risperidone | 40 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 37 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Simvastatin | Simvastatin | 37 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Timolol Maleate | Timolol Maleate | 36 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 19 |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 32 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 15 |
| Glipizide | Glipizide | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 25 |
| Nystatin | Nystatin | 31 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Brilinta | Ticagrelor | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 18 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 19 |
| Vraylar | Cariprazine Hcl | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 16 |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 12 |
| Lithium Carbonate | Lithium Carbonate | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 25 | 14 |
| Paliperidone Er | Paliperidone | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Admelog Solostar | Insulin Lispro | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Calcium Acetate | Calcium Acetate | 22 | suppressed |
| Creon | Lipase/Protease/Amylase | 22 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | 11 |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 18 |
| Primidone | Primidone | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Nyamyc | Nystatin | 16 | 14 |
| Tradjenta | Linagliptin | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Tresiba | Insulin Degludec | 14 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Levocarnitine | Levocarnitine | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | 12 |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $42.02 · 2 records | Neurocrine BioSciences, Inc. | INGREZZA, REXULTI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Neurocrine BioSciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error